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Introduction and background
===========================

Acute pancreatitis is a common inflammatory condition of the pancreas with various underlying etiologies. Gallstones and alcohol are among the most common while drug-induced disease, autoimmune conditions, viral infections, trauma, and malignancy are less common causes \[[@REF1]-[@REF3]\]. However, relatively infrequent hypertriglyceridemia is one of the known etiologies of acute pancreatitis \[[@REF4]\]. In patients with hypertriglyceridemic pancreatitis (HTGP), a pre-existing lipid abnormality has commonly been documented. According to prior research, the risk of acute pancreatitis increases significantly when serum hypertriglyceridemia exceeds 1,000 mg/dL (normal, 101-150 mg/dL) \[[@REF5]\]. The concomitant presence of single or multiple secondary precipitating factors, including poorly controlled diabetes mellitus, alcohol consumption, or therapy with certain medications, are also implicated in the pathogenesis of HTGP. Similarly, genetic factors may also be deemed responsible for altering the normal lipid metabolism in these patients \[[@REF6]\].

The overall mortality following acute pancreatitis has been described up to 5%; however, it is relatively higher among hospitalized patients \[[@REF6]\]. HTGP frequently culminates in a severe disease presentation with an increased propensity to cause life-threatening complications. In this context, an effective and feasible treatment of choice is particularly warranted. The major goal of therapy is to relieve pain and avoid any inadvertent events. In the current times, a specific therapeutic approach is non-existent. Conservative management, using the variable combinations of intravenous hydration, analgesics, and antibiotics, is important for the initial resuscitation. Although heparin and insulin have been used, plasmapheresis and lipid apheresis are becoming more popular management options for hyperlipidemic pancreatitis \[[@REF7]\]. However, the widespread availability of these techniques may pose a therapeutic dilemma. This review outlines our current understanding of the epidemiology and risk factors for HTGP, the pathophysiology of this disorder, and currently available approaches to diagnosis and treatment. We highlight insulin therapy as a feasible therapeutic option in these patients, especially if plasmapheresis is not available.

Review
======

Epidemiology

HTGP is a known clinical entity with an estimated incidence ranging from 2.3% to 10% of all cases of acute pancreatitis \[[@REF7]\]. It often involves male individuals with age less than 50 years who have severe hypertriglyceridemia. According to a prospective study of 400 cases of acute pancreatitis, patients with hypertriglyceridemia were younger, obese, predominantly of the male gender, diabetic, and had a history of more frequent episodes of persistent organ failure \[[@REF8]\]. Furthermore, hypertriglyceridemia is commonly encountered in pregnancy due to physiological changes and, occasionally, it may lead to acute pancreatitis. The incidence of HTGP during pregnancy has been described to be 1 in 25,000 pregnancies.

Pathogenesis

Although the exact pathogenesis of HTGP is unknown, the proposed mechanism implicates the toxic effects of free fatty acids released by the breakdown of triglycerides \[[@REF9]\]. Triglyceride-rich lipoproteins such as chylomicrons and very low-density lipoproteins (VLDLs) are large molecules that are found in abundance in conditions like hypertriglyceridemia. These molecules may occlude the pancreatic capillaries and subsequently change the structure of the acinar cells. This process eventually triggers the release of pancreatic enzymes, including lipases that catabolize the lipid-rich molecules. This breakdown results in increased local oxidative stress that further contributes to the inflammatory response in the pancreas, resulting in the symptomatology of acute pancreatitis \[[@REF9]\].

Search criteria

We conducted an extensive literature search of Google Scholar and PubMed (National Library of Medicine, Bethesda, MD) using a combination of terms, including "hypertriglyceridemia," "pancreatitis," "insulin," and "treatment." A total of 147 studies were initially obtained, consisting of but not limited to original articles, case series, and case reports as of July 2018. After excluding 39 duplicate articles, 108 papers were thoroughly studied. The articles available in any language other than the English were excluded from the review. Forty-eight papers were found relevant to the scope of our study but 34 cases were found accessible in order to retrieve pertinent data required for this review \[[@REF10]-[@REF31]\]. The data on individual cases of HTGP on epidemiology, clinical presentation, diagnosis, management, and clinical outcomes are summarized in Table [1](#TAB1){ref-type="table"}.

###### Literature review of insulin treatment in patients with hypertriglyceridemia-associated acute pancreatitis

TG, triglyceride; HTG, hypertriglyceridemia; OCPs, oral contraceptive pills; DM, diabetes mellitus; U, unit; D5W, dextrose 5% in water; HTN, hypertension; HLD, hyperlipidemia; CD, Crohn's disease; MI, myocardial infarction; CABG, coronary artery bypass graft; RE, reflux esophagitis; BD, bipolar disorder; IBS; irritable bowel syndrome; GAD, generalized anxiety disorder; AP; acute pancreatitis; DKA; diabetic ketoacidosis; OSA, obstructive sleep apnea; NA, not available

\*After acute phase of insulin treatment

  -------------------------------------- ------------ --------------------------------------------------- --------------------------------------------- -------------------------- -------------------------------------------------------------------------- --------------------------- ------------------------------ ---------------------------------------------
  Authors                                Age/Gender   Clinical presentation                               Comorbidity                                   Initial TG level (mg/dL)    Treatment                                                                 TG post-treatment (mg/dL)   Duration of treatment (days)   Outcome
  Jabbar et al. 1998 \[[@REF10]\]        13/M         Abdominal pain                                      HTG                                           4574                       Regular insulin injection (0.1 U/kg/h), fish oil, gemfibrozil              565\*                       1                              Recovered
  Huang et al. 2002 \[[@REF11]\]         41/F         Abdominal pain, nausea, vomiting                    HTG, OCPs                                     2260                       Insulin-glucose infusion                                                   314                         3                              Recovered
  Mikhail et al. 2005 \[[@REF12]\]       38/F         Excruciating abdominal pain                         HTG                                           10, 560                    Subcutaneous insulin lispro, sliding scale                                 712                         3                              Recovered
  Alagozlu et al. 2006 \[[@REF13]\]      44/M         Abdominal pain, vomiting                            DM type 2                                     1707                       Regular insulin 3 U/h, D5W, 5000 U of heparin                              180                         10                             Recovered
  Gursoy et al. 2006 \[[@REF14]\]        24/F         Severe abdominal pain, fever, vomiting, malaise     Pregnancy                                     10,092                     Intravenous insulin, glucose                                               608                          5                             Recovered
  Jain et al. 2007 \[[@REF15]\]          55/M         Abdominal pain, vomiting                            Recurrent acute pancreatitis                   1808                      Regular insulin infusion, D5W, 5000 U heparin subcutaneously twice a day   325                         5                              Recovered
  Jain et al. 2007 \[[@REF15]\]          46/M         Abdominal pain, vomiting                            DM, recurrent pancreatitis                    3743                       Regular insulin infusion, D5W, 5000 U heparin subcutaneously twice a day   350                         5                              Recovered
  Love et al. 2009 \[[@REF16]\]          34/F         Abdominal pain, nausea, vomiting, diarrhea          HTN, HLD, CD, cholecystectomy                 10,039                     Sliding scale insulin, gemifibrozil                                        646                         9                              Recovered
  Jain et al. 2009 \[[@REF17]\]          54/M         Acute epigastric pain                               DM, HTG                                       10,320                     Regular insulin infusion, D5W, heparin                                     1386                        6                              Recovered
  Hahn et al. 2010 \[[@REF18]\]          20/F         Epigastric pain, vomiting, diarrhea                 DM type 1                                     15,240                     Continuous insulin infusion, 3% NaCl solution for pseudohyponatremia       309                         22                             Recovered
  Twilla et al. 2012 \[[@REF19]\]        39/M         Abdominal pain, nausea, and vomiting                HTG                                           5366                       Continuous insulin infusion and subcutaneous heparin                       717                         5                              Recovered
  Patel et al. 2012 \[[@REF20]\]         42/F         Abdominal pain, vomiting                            DM type 2, type 5 HTG                         \>5000                     Insulin infusion 0.1 U/kg/h, D5W, heparin 600 U/h                          923                         1                              Recovered
  Weston et al. 2013 \[[@REF21]\]        46/M         Abdominal pain, eruptive xanthomas arms and torso   2 MIs status post CABG surgery and stenting   3026                       Insulin-heparin infusion                                                   NA                          NA                             Recovered
  Denecker et al. 2013 \[[@REF22]\]      23/F          Epigastric pain, nausea                            DM type 2, RE                                 12,851                     Intravenous fluid, insulin, analgesics                                     549                         12                             Recovered
  Coskun et al. 2015 \[[@REF23]\]        41/M         Abdominal pain, nausea, vomiting                    HTG                                           1118                       Regular insulin infusion, D5W                                              355                         3                              Recovered
  Coskun et al. 2015 \[[@REF23]\]        48/F         Abdominal pain, nausea, vomiting                    DM                                            1176                       Regular insulin infusion, D5W                                              464                         3                              Recovered
  Coskun et al. 2015 \[[@REF23]\]        54/M         Abdominal pain, nausea, vomiting                    HTG                                           1228                       Intravenous regular insulin infusion in D5W                                489                         3                              Recovered
  Coskun et al. 2015 \[[@REF23]\]        35/M         Abdominal pain, vomiting                            DM                                            1027                       Regular insulin infusion, D5W                                              496                         3                              Recovered
  Coskun et al. 2015 \[[@REF23]\]        43/F         Abdominal pain, nausea, vomiting                    HTG                                           1004                       Intravenous regular insulin infusion in D5W                                476                         3                              Recovered
  Coskun et al. 2015 \[[@REF23]\]        30/F         Abdominal pain, nausea, vomiting                    HTG                                           1086                       Intravenous regular insulin infusion in D5W                                481                         3                              Recovered
  Coskun et al. 2015 \[[@REF23]\]        59/M         Abdominal pain, nausea, vomiting                    DM                                            1130                       Regular insulin infusion, D5W                                              373                         5                              Recovered
  Coskun et al. 2015 \[[@REF23]\]        46/M         Abdominal pain, nausea, vomiting                    DM                                            1156                       Intravenous regular insulin infusion in D5W                                498                         3                              Recovered
  Coskun et al. 2015 \[[@REF23]\]        40/F         Abdominal pain, vomiting                            DM                                            1124                       Regular insulin infusion, D5W                                              494                         3                              Recovered
  Coskun et al. 2015 \[[@REF23]\]        45/M         Abdominal pain, nausea, vomiting                    DM                                            1235                       Intravenous regular insulin infusion in D5W                                276                         5                              Recovered
  Coskun et al. 2015 \[[@REF23]\]        65/M         Abdominal pain, vomiting                            DM                                            1190                       Intravenous regular insulin infusion in D5W                                356                         5                              Recovered
  Coskun et al. 2015 \[[@REF23]\]        46/M         Abdominal pain, nausea, vomiting                    DM                                            1215                       Regular insulin infusion, D5W                                              298                         5                              Recovered
  Franco et al. 2015 \[[@REF24]\]        50/M         Severe epigastric pain                              BD, HLD, DM type 2, obesity, IBS, GAD         3590                       Insulin infusion                                                           684                         3                              Recovered
  Khan et al. 2015 \[[@REF25]\]          44/F         Abdominal pain, vomiting                            HTN                                           3525                       Insulin infusion                                                           675                         3                              Recovered
  Singla et al. 2015 \[[@REF26]\]        19/M         Epigastric pain, nausea, polyuria                   Obesity, DM                                   4009                       Insulin infusion 6 U/h, D5W, fenofibrate                                   180                         1                              Recovered
  Amin et al. 2015 \[[@REF27]\]          40/F         Abdominal pain, vomiting, diarrhea                  Graves diseases, HTG, pregnancy               4106                       Low-dose insulin on sliding scale                                          885                         8                              Recovered
  Abraham et al. 2015 \[[@REF28]\]       24/F         Abdominal pain, nausea, vomiting                    Asthma, OCP Estrostep                         2200                       Insulin infusion, omega-3 fatty acids, gemifibrozil                        355                          7                             Recovered
  Aryal et al. 2016 \[[@REF29]\]         31/M         Epigastric pain                                     Obesity, HLD, HTN, DM type 2                  15,215                     Regular insulin (0.4 U/kg/h), heparin infusion                             363                         6                              Recovered
  Jeon et al. 2017 \[[@REF30]\]          28/F         Epigastric pain                                     HLD, Pregnancy                                10,392                     Insulin injection                                                          No improvement              NA                              Died (cardiac arrest after AP-related DKA)
  Chaudhary et al. 2017 \[[@REF31]\]     44/M         Epigastric pain, vomiting                           DM, HTG, HTN, obesity, OSA                    6,672                      Insulin infusion 0.1 u/kg/h, D5W 75 cc/h                                   500                         8                              Recovered
  -------------------------------------- ------------ --------------------------------------------------- --------------------------------------------- -------------------------- -------------------------------------------------------------------------- --------------------------- ------------------------------ ---------------------------------------------

Patient demographics and clinical presentations

In the present review, HTGP involved all age groups, with the mean age of 39.6 years (range: 13-65 years). There was no clear gender preponderance (male, n = 18; female, n = 16). The typical presentation was acute-onset abdominal pain while other notable symptoms included nausea and vomiting. Cutaneous signs of hypertriglyceridemia such as eruptive xanthomas over the extensor surfaces of the arms, legs, and buttocks were also noted in a few patients. A majority of patients had comorbid conditions and risk factors like moderate-to-severe hypertriglyceridemia, hypertension, diabetes mellitus, dyslipidemias, pregnancy, alcohol abuse, oral contraceptive use, and obesity. It was an interesting observation that the initial triglyceride levels causing acute pancreatitis were more than 1000 mg/dL in all cases included in this review. It was further notable that there were a few cases where HTGP occurred in pregnant patients. Although pregnancy is associated with an overall increase in the serum triglyceride level, it rarely exceeds 300 mg/dL in most pregnant females.

Diagnosis

The diagnostic criteria for HTGP include the presence of at least two out of three following findings: (a) acute-onset severe epigastric pain radiating to the back; (b) serum lipase or amylase elevated three or more times the upper reference limit; and (c) the three characteristic findings of acute pancreatitis on imaging investigations such as computed tomography, magnetic resonance imaging, or transabdominal ultrasonography \[[@REF32]\]. Another major clue for the diagnosis of HTGP includes biochemical evaluation remarkable for serum triglyceride levels more than 1000 mg/dL. The risk factors for hypertriglyceridemia are obesity, pregnancy, family history of hypertriglyceridemia, poorly-controlled diabetes mellitus, and alcoholism\[[@REF32]\]. It is important to mention here that a thorough clinical history, including family history of lipid metabolic aberrations and physical examination to identify eruptive xanthomas, can help to channelize the biochemical and radiological investigations toward a timely etiology establishment.

Insulin therapy

Currently, there are no clear therapeutic guidelines for HTGP. Insulin therapy has previously been used in these patients as a minimally invasive and economical strategy with promising outcomes \[[@REF33]-[@REF34]\]. The mechanism by which insulin lowers the level of serum triglycerides is by triggering the enzymatic activity of lipoprotein lipase and inhibition of hormone-sensitive lipase. Lipoprotein lipase metabolizes chylomicrons and VLDLs into the free fatty acids and glycerol. Therefore, it ultimately decreases the serum triglyceride levels. Decreasing the activity of hormone-sensitive lipase causes decreased adipocyte-triglyceride breakdown, resulting in a decreased release of free fatty acids into the circulation, which controls the toxic effects on the pancreas, limiting its active inflammation \[[@REF35]\]. In this review, the initial symptomatic management comprised of bowel rest, intravenous fluids, and analgesics. In regard to the emergency management of HTGP, insulin infusion as monotherapy or part of a combination regimen was the most effective option in settings where plasmapheresis was not available or as an alternative approach for patients who could not tolerate apheresis. It was usually given intravenously at a rate of 0.1-0.3 units/kg/hour. Serum triglyceride levels were monitored every 12 hours. With insulin therapy, it was pivotal to measure blood glucose levels and adjuvant 5% dextrose infusion was required when the blood glucose level fell below 200 mg/dL.

Clinical outcomes

According to the results of the outcome analysis of this review, the overall prognosis of HTGP was good with a vast majority of patients recovering completely with intensive insulin therapy. It is quite reassuring that in emergency clinical settings, intravenous insulin was used as a salvage therapy, even in patients with severe HTGP, resulting in a remarkable recovery. In three to five days of insulin therapy, most patients demonstrated a good clinical response; serum triglyceride levels decreased to less than 500 mg/dL after which the treatment was discontinued. A number of patients received insulin as a combination therapy with lipid-lowering drugs. In our review, one patient died from HTGP due to cardiac arrest, which was thought to occur as a sequel to severe metabolic acidosis and electrolyte imbalance. This fatal outcome re-emphasizes that patients with HTGP are more likely to encounter organ failure as compared to the other causes of pancreatitis. Therefore, urgent and appropriate management is essentially important.

Long-term management

Patients with HTGP clinically improve when the serum triglyceride levels fall below 500 mg/dL. However, in order to prevent recurrent episodes and subsequent complications of HTGP, long-term management is warranted to maintain the level of triglycerides below 200 mg/dL. It is particularly tailored to lifestyle modifications with dietary fat and sugar restriction, aerobic exercises, weight loss, and blood sugar control. The hypolipidemic medications like gemfibrozil and fenofibrate lower serum triglyceride levels and reduce the recurrence risk of HTGP \[[@REF36]-[@REF37]\].

Future directions

A prospective randomized controlled trial showed that early high-volume hemofiltration can lower triglyceride levels more efficiently than low-molecular-weight heparin combined with insulin therapy, but it was not superior in terms of clinical outcomes and cost \[[@REF38]\]. Therefore, the determination of relative efficacy, meticulous risk stratification, and mortality benefits of currently used techniques, that is, insulin therapy and plasmapheresis warrant further research. Randomized clinical trials in the future may help untangle this uncertainty about the best technique in regards to the emergency management of HTGP.

Conclusions
===========

Patients with HTGP require urgent management as the disease presentation is particularly severe and it may result in grave complications. The use of insulin therapy with close monitoring of blood glucose levels can be an appropriate therapeutic approach, especially in cases with no availability of apheresis. This paper not only highlights the utility of insulin therapy for HTGP but also sensitizes concerned physicians to evaluate this treatment approach in larger, multicenter studies. Long-term management using pharmacological and non-pharmacological therapies, directed at maintaining the serum triglycerides within normal limits, is required to prevent recurrent attacks of HTGP.
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